LMBio Overview
- Founded
- 2020
- Status
- Private
- Latest Deal Type
- Early Stage VC
- Investors
- 4
LMBio General Information
Description
Developer of biotech innovative drugs. The company focuses on the development of cellular immunotherapy products with TILs therapy, its main research and development direction is to genetically modify TILs cells to improve the efficacy of TIL treatment, the comprehensive treatment mode of TIL treatment combined with other immunotherapy, targeted therapy or radiotherapy and chemotherapy, and the development of new gene carriers to transport specific T cells to tumors, providing cancer patients with new options and treatment options.
Contact Information
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
- 4th and 5th Floor, Building 13, No. 168
- Majian Road, Suzhou High-tech Zone
- Suzhou, Jiangsu
- China
LMBio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Early Stage VC | 01-Feb-2022 | Completed | Startup | |||
| 1. Early Stage VC | 20-Apr-2021 | Completed | Startup |
LMBio Executive Team (1)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Xiaotong Zhao | Chairman & General Manager |
LMBio Board Members (1)
| Name | Representing | Role | Since |
|---|---|---|---|
| Xiaotong Zhao | LMBio | Chairman & General Manager | 000 0000 |
LMBio Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| BioTrack Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
| IDG Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
| SND Ventures Group | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Huagai Capital | Venture Capital | Minority | 000 0000 | 000000 0 |